Bausch Health's Acne Treatment Now Available Through Public Drug Plans

Bausch Health, Canada Inc. has announced that its acne treatment, CABTREO, is accessible through Ontario and Nova Scotia's public drug plans and two federal programs — the Non-Insured Health Benefits for Indigenous populations and the Correctional Service of Canada.

CABTREO is a triple-combination topical gel containing clindamycin phosphate, adapalene, and benzoyl peroxide, targeting acne vulgaris for individuals aged 12 and older. It is the sole Health Canada-approved treatment with an antibiotic, a retinoid, and an antibacterial agent. Clinical trials demonstrated approximately 50% treatment success by reducing more than 70% of inflammatory and non-inflammatory lesions at 12 weeks.

The gel, applied once daily, may cause skin reactions and should not be used by pregnant women or those with certain conditions. Bausch Health is working on listing arrangements with additional public drug plans across Canada.